Cytek Biosciences, Inc.

CTKB • Medical - Devices

$4.70

— 0.00 (0.00%)

Current price

EarningsLatest report: Jun 30, 2026

BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.

Market Cap

$608.46M

Growth

23.9%

Cash Flow

3/5

Trend

Mostly stable

Evidence

Positive revenue growth · 13.3%Manageable debt level · 0.07Healthy liquidity · 5.04Weak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 1:23 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$4.70

Change0.00%

Shares Out129.46M

Market Cap$608.46M

Enterprise Value$356.14M

52W Range3.28 - 6.18

Beta1.17

P/E-7.55

P/S2.94

P/B1.89

P/FCF-35.83

EV/Sales1.72

Price$4.70

Change0.00%

Shares Out129.46M

Market Cap$608.46M

Enterprise Value$356.14M

52W Range3.28 - 6.18

Beta1.17

P/E-7.55

P/S2.94

P/B1.89

P/FCF-35.83

EV/Sales1.72

EV/EBITDA-11.31

EV/FCF-20.97

Earnings Yield-13.24%

FCF Yield-2.79%

Dividend Yield0.00%

Gross Margin51.84%

Oper. Margin-20.04%

Profit Margin-33.02%

Debt/Eq0.07

Current Ratio5.04

Quick Ratio4.42

Revenue 5Y23.94%

Target$4.88

Target Upside3.83%

Target Median$4.88

Target Range4.75 - 5.00

Volume1.32M

Avg Volume1.36M

EPS Surprise-0.04

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

95/100

Price Attractiveness

Cheap or expensive today

82/100

Why this score▼

Positive revenue growth · 13.3%Manageable debt level · 0.07Healthy liquidity · 5.04Weak profitability

Analyst view

Analyst sentiment and price target

CTKB

Analyst sentiment

Based on 5 analyst votes · 2026-09-05

70/100

Bullish

Hold

Bearish

Price Target

2026-08-07

Low

$4.75

Mean

$5.13

Median

$5.13

High

$5.50

Company Overview

IPO: 7/23/2021

Industry: Medical - Devices

P/B i: 1.89

Debt / Equity i: 0.07

Operating Margin: -20.04%

Net Margin: -33.02%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.07

Current Ratio: 5.04

Quick Ratio: 4.42

Status: Good

Insider Transactions

Recent executive and insider activity

⚠ 1 high-volume insider sell detected

Feuchtwang Ilan

Transaction: 06/29/2026

OTHER

Change

Price

Not reported

Filing

06/30/2026

Type

OTHER

Yan Ming

Transaction: 06/12/2026

SELL

Change

-135,892

Price

Not reported

Filing

06/16/2026

Type

SELL

Holder Michael

Transaction: 06/10/2026

BUY

Change

+18,261

Price

$4.05

Filing

06/12/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Feuchtwang Ilan	OTHER	0	Not reported	06/29/2026	06/30/2026
Yan Ming	SELL	-135,892	Not reported	06/12/2026	06/16/2026
Holder Michael	BUY	+18,261	$4.05	06/10/2026	06/12/2026
Holder Michael	SELL	-43,973	Not reported	06/10/2026	06/12/2026
Holder Michael	BUY	+43,973	Not reported	06/10/2026	06/12/2026
NEFF DEBORAH J	BUY	+18,261	$4.05	06/10/2026	06/12/2026
NEFF DEBORAH J	SELL	-43,973	Not reported	06/10/2026	06/12/2026
NEFF DEBORAH J	BUY	+43,973	Not reported	06/10/2026	06/12/2026
Imper Vera	BUY	+18,261	$4.05	06/10/2026	06/12/2026
Imper Vera	SELL	-43,973	Not reported	06/10/2026	06/12/2026
Imper Vera	BUY	+43,973	Not reported	06/10/2026	06/12/2026
Chin Richard	BUY	+18,261	$4.05	06/10/2026	06/12/2026
Chin Richard	BUY	+33,333	Not reported	06/10/2026	06/12/2026
MUIR GLENN P	OTHER	0	Not reported	06/10/2026	06/12/2026
MUIR GLENN P	BUY	+29,835	$4.05	06/10/2026	06/12/2026
MUIR GLENN P	BUY	+55,555	Not reported	06/10/2026	06/12/2026
Ball Jack	SELL	-43,973	Not reported	06/10/2026	06/12/2026
Ball Jack	BUY	+43,973	Not reported	06/10/2026	06/12/2026
Barnett Valerie	SELL	-881	$3.55	05/18/2026	05/20/2026
Barnett Valerie	SELL	-2,454	Not reported	05/18/2026	05/20/2026

About the Company

Cytek Biosciences, Inc.

Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell analysis by leveraging fluorescence signatures from multiple lasers to differentiate between various fluorescent tags on individual cells. Complementing these, the Aurora Cell Sorter system utilizes full spectrum profiling technology to broaden the range of potential applications in cell analysis. Beyond instrumentation, Cytek provides essential reagents and kits. These include cFluor reagents, which are antibodies conjugated with fluorochromes, specifically designed to identify target cells for analysis on their systems. They also offer a 25-color immunoprofiling assay, a ready-to-use solution for pinpointing major human immune cell subpopulations like TBNK cells, monocytes, dendritic cells, and basophils. To streamline laboratory operations, the company offers automated micro-sampling and sample loader systems. These automated plate loaders are engineered to integrate seamlessly with the Aurora and Northern Lights systems. The intuitive SpectroFlo software accompanies these systems, simplifying the workflow from quality control through to data analysis. Cytek also provides comprehensive customer support resources. Cytek's diverse client base includes pharmaceutical and biopharmaceutical companies, academic research institutions, and clinical research organizations. The company distributes its products through a direct sales force and dedicated support teams in North America, Europe, China, and the Asia-Pacific region. Additionally, it partners with distributors and sales agents to serve markets across European, Latin American, Middle Eastern, and other Asia-Pacific countries. Originally established in 1992 as Cytoville, Inc., the company officially adopted the name Cytek Biosciences, Inc. in August 2015. Its corporate headquarters are situated in Fremont, California.

Source - link

Peers

ANGO AVNS CBLL CLPT KIDS LAB ORGO SRDX TMCI VREX

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS

FREMONT, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- As clinical laboratories seek deeper cellular insights, greater efficiency, and more streamlined approaches to cell analysis, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its advanced solutions at two leading clinical cytometry events this fall: the European Society for Clinical Cell Analysis (ESCCA) 2026 Conference and ICCS 2026, the 41st Annual International Clinical Cytometry Meeting & Course.

GlobeNewsWire

Deutsche Bank AG Makes New $496,000 Investment in Cytek Biosciences, Inc. $CTKB

Deutsche Bank AG bought a new position in Cytek Biosciences, Inc. (NASDAQ: CTKB) in the quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 111,932 shares of the company's stock, valued at approximately $496,000. Deutsche Bank AG owned approximately 0.09% of Cytek Biosciences as of

Defense World

Cytek Biosciences to Participate in Upcoming Investor Conferences

FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences.

GlobeNewsWire

Jury Finds in Cytek's Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding

FREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences,” “Cytek,” or the “Company”) (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc. The jury found in Cytek's favor on three of the four asserted patent claims, finding noninfringement and invalidity as to each of those three claims. With respect to one claim, the jury found no literal infringement but found infringement under the doctrine of equivalents. The jury awarded past damages consisting of $20 million in lost profits and $36 million in royalties. Cytek intends to pursue post-verdict motions challenging the finding of infringement under the doctrine of equivalents and the related damages award.

GlobeNewsWire

Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript

Seeking Alpha

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-07	-0.08	-0.12	-0.04
2026-02-26	-0.02	-0.01	0.01
2025-11-05	0.01	-0.01	-0.02
2025-08-06	-0.02	0.01	0.03
2025-05-08	-0.04	-0.09	-0.05
2025-02-27	0.05	0.07	0.02
2024-11-05	0.00375	0.01	0.00625
2024-08-06	-0.03	-0.08	-0.05
2024-05-08	-0.05	-0.05	0
2024-02-28	0.03	0.07	0.04
2023-11-07	-0.33333	0.01	0.34333
2023-08-08	-0.01	0.01	0.02